Mutation-Free Expression of c-Kit and PDGFRA in Phyllodes Tumors of the Breast.
10.4048/jbc.2010.13.3.257
- Author:
Chang Woo JUNG
1
;
Kwang Sun SUH
;
Jin Sun LEE
;
Je Ryong KIM
;
Eil Sung CHANG
;
Hae Joung SUL
;
Mee Ja PARK
Author Information
1. Department of Pathology, Research Institute for Medical Sciences, Chungnam National University School of Medicine, Daejeon, Korea. kssuh@cnu.ac.kr
- Publication Type:Original Article
- Keywords:
Breast;
Mutation;
Phyllodes tumor;
Platelet-derived growth factor receptor alpha;
Proto-oncogene proteins c-kit
- MeSH:
Breast;
Exons;
Humans;
Phyllodes Tumor;
Proto-Oncogene Proteins c-kit;
Receptors, Platelet-Derived Growth Factor;
Recurrence
- From:Journal of Breast Cancer
2010;13(3):257-266
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Phyllodes tumors (PTs) of the breast have been classified as benign, borderline, or malignant based on their histopathologic features. However, predicting clinical behavior based on these features has proven to be difficult given that local recurrence occurs in both benign and malignant PTs. Recurrence has been shown to mirror the histologic pattern of the primary tumor or to show dedifferentiation. The aim of this study was to assess the value of the histopathologic parameters, expression or mutation of c-Kit and platelet derived growth factor receptor alpha (PDGFRA) in predicting tumor recurrence. METHODS: Representative areas from 39 benign, 16 borderline, and 12 malignant PTs were selected for construction of tissue microarrays. Immunohistochemical analyses for p53, Ki-67, c-Kit, and PDGFRA were performed and SSCP-PCR analysis was carried out to identify mutations in exons 9, 11, 13, and 17 of the c-Kit gene and exons 12 and 18 of the PDGFRA gene. Clinicopathologic features, including tumor recurrence and margin status, were also evaluated. RESULTS: Of the 67 PTs, 11 cases (16.4%) recurred from 3 to 92 months following initial diagnosis (4 benign, 2 borderline, and 5 malignant). One benign PT case recurred as a borderline tumor and two borderline PT cases recurred as malignancies. Three patients died of malignant PT. No mutations of the c-Kit or PDGFRA genes were found and there was no statistically significant association of either p53 or p16 immunostaining with recurrent disease (p>0.05). However, histologic grade (p=0.033), margin status (p<0.001), Ki-67 (p=0.012), c-Kit (p=0.002), and PDGFRA (p=0.007) stromal immunopositivity were significantly correlated with recurrence. CONCLUSION: Even though positive or close margins were significantly associated with tumor recurrence, stromal c-Kit, PDGFRA positivity, and the Ki-67 index were useful for predicting recurrent PTs. Despite this, no c-Kit or PDGFRA mutations were found.
